TuHURA Biosciences(DE:PL3)
€1.440.01 (-0.69%)
DE:PL3
TuHURA Biosciences financials statements
€1.44
At close:0.01 (-0.69%)
TuHURA Biosciences (PL3) Ratios
3 Followers
TuHURA Biosciences Ratios
DE:PL3's free cash flow for Q2 2026 was $-8.77M. For the 2026 fiscal year, DE:PL3's free cash flow was decreased by $-136.98K and operating cash flow was $-8.63M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.78 | 3.68 | 1.16 | 5.13 | 0.79 |
| Quick Ratio | 0.78 | 3.64 | 1.16 | 5.13 | 0.79 |
| Cash Ratio | 0.61 | 2.37 | 1.02 | 4.96 | 0.78 |
| Solvency Ratio | -4.67 | -4.01 | -4.92 | -3.11 | -0.93 |
| Operating Cash Flow Ratio | -4.67 | -2.76 | -3.32 | -2.61 | -0.92 |
| Short-Term Operating Cash Flow Coverage | -140.00 | 0.00 | 0.00 | 0.00 | -10.19 |
| Net Current Asset Value | $ -1.80M | $ 14.24M | $ -1.76M | $ 11.85M | $ -1.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.01 | 0.54 | 0.01 | 0.10 |
| Debt-to-Equity Ratio | 0.03 | 0.01 | -1.50 | 0.01 | -0.86 |
| Debt-to-Capital Ratio | 0.03 | 0.01 | 2.98 | 0.01 | -6.21 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.00 | 3.04 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.31 | 1.37 | -2.80 | 1.24 | -8.56 |
| Debt Service Coverage Ratio | -35.68 | -4.21 | -1558.26 | 0.00 | -4.72 |
| Interest Coverage Ratio | -50.85 | -4.26 | -1592.72 | 0.00 | -11.53 |
| Debt to Market Cap | 0.01 | 0.00 | 0.55 | 0.00 | 0.91 |
| Interest Debt Per Share | 0.03 | 0.23 | 3.14 | 2.99 | 45.76 |
| Net Debt to EBITDA | 0.10 | 0.71 | 0.05 | 1.48 | 0.82 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.54% | 122.85% | 98.50% | 94.30% | 96.71% |
| Return on Assets (ROA) | -109.90% | -108.59% | -672.13% | -61.64% | -109.59% |
| Return on Equity (ROE) | -143.61% | -148.57% | 1880.80% | -76.13% | 938.26% |
| Return on Capital Employed (ROCE) | -148.34% | -120.58% | -3888.72% | -80.60% | 970.15% |
| Return on Invested Capital (ROIC) | -145.65% | -119.28% | -3785.74% | -79.84% | 6992.69% |
| Return on Tangible Assets | -180.92% | -108.59% | -672.13% | -61.64% | -109.59% |
| Earnings Yield | -82.89% | -28.41% | -699.06% | -2937.41% | -988.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.58 | -0.79 | -15.87 | -162.22 | -235.85 |
| Free Cash Flow Per Share | -0.58 | -0.79 | -15.98 | -163.00 | -235.96 |
| Dividend Paid and CapEx Coverage Ratio | -327.21 | -254.35 | -150.85 | -32.36 | -581.86 |
| Capital Expenditure Coverage Ratio | -363.14 | -254.35 | -150.85 | -32.36 | -2001.02 |
| Operating Cash Flow Coverage Ratio | -39.47 | -72.72 | -5.10 | -54.32 | -10.19 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -76.39% | -19.37% | -286.86% | -2365.77% | -925.35% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.20 | -3.37 | -0.14 | -0.03 | -0.10 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.73 | 5.23 | -2.69 | 0.03 | -0.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.31 | -5.16 | -0.35 | -0.04 | -0.11 |
| Price-to-Operating Cash Flow Ratio | -1.31 | -5.18 | -0.35 | -0.04 | -0.11 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | -1.14 | -3.67 | -0.10 | 1.44 | 0.70 |
| Enterprise Value | 33.35M | 63.88M | 2.87M | -13.80M | -4.19M |
| EV to EBITDA | -1.14 | -3.67 | -0.10 | 1.44 | 0.70 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.20 | -4.32 | -0.24 | 1.83 | 0.64 |
| EV to Operating Cash Flow | -1.21 | -4.34 | -0.24 | 1.84 | 0.64 |
| Tangible Book Value Per Share | 0.21 | 0.78 | -2.07 | 265.83 | -26.87 |
| Shareholders’ Equity Per Share | 0.44 | 0.78 | -2.07 | 265.83 | -26.87 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.63 | -1.16 | -38.94 | -202.39 | -252.13 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 1.24 | 1.00 | 0.94 | 1.10 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 0.68 | 0.41 | 0.80 | 0.94 |
Currency in USD
